Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.125 10.87% 1.275 27,911,942 15:26:34
Bid Price Offer Price High Price Low Price Open Price
1.25 1.30 1.275 1.125 1.175
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.62 -8.88 -0.70 15
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:16 O 592,577 1.275 GBX

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix (TRX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

DateSubject
25/1/2020
08:20
Tissue Regenix Daily Update: Tissue Regenix Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 1.15p.
Tissue Regenix Group Plc has a 4 week average price of 0.93p and a 12 week average price of 0.48p.
The 1 year high share price is 8.50p while the 1 year low share price is currently 0.48p.
There are currently 1,171,730,823 shares in issue and the average daily traded volume is 51,237,561 shares. The market capitalisation of Tissue Regenix Group Plc is £14,939,567.99.
24/1/2020
08:43
the stigologist: This is and remains my position. Bought more. Happy to buy from the stupid/desperate. We knew they were looking at 'recapitalisation' (that can be via placing, rights issue, disposals/divestments) but they've already demonstrated they can expand cash runway in meantime whilst they consider best options From 'at least to end of March' to 'at least to end of April' That is a full 3 months which gives plenty of time for more -cash management, cash generation etc -disposals/divestments -placing / rights issue (I have stated my preference for a rights issue as it gives holder pre-emption rights to the clear and evident mega upside) With 3 months cash runway they can leave the worst of those recapitalisation options (placing) to March. Right Issue might require a bit more time to arrange, get documentation sent out etc. Either way TRX is only at 1.2p because of Woodford overhang NAV/share is 3p+ Typically in growth industries and market-leading Companies tend to trade at premia to NAV because that is what a new entrant would have to pay to replicate that position So we should be looking at a share price of 6p+ The fact the Chairman John Samuel bought at 10p is a further signal that value is SIGNIFICANTLY in excess of 1.2p here
23/1/2020
11:45
the stigologist: Bought more. Happy to buy from the stupid/desperate. We knew they were looking at 'recapitalisation' (that can be via placing, rights issue, disposals/divestments) but they've already demonstrated they can expand cash runway in meantime whilst they consider best options From 'at least to end of March' to 'at least to end of April' That is a full 3 months which gives plenty of time for more -cash management, cash generation etc -disposals/divestments -placing / rights issue (I have stated my preference for a rights issue as it gives holder pre-emption rights to the clear and evident mega upside) With 3 months cash runway they can leave the worst of those recapitalisation options (placing) to March. Right Issue might require a bit more time to arrange, get documentation sent out etc. Either way TRX is only at 1.2p because of Woodford overhang NAV/share is 3p+ Typically in growth industries and market-leading Companies tend to trade at premia to NAV because that is what a new entrant would have to pay to replicate that position So we should be looking at a share price of 6p+ The fact the Chairman John Samuel bought at 10p is a further signal that value is SIGNIFICANTLY in excess of 1.2p here
22/1/2020
10:24
the stigologist: We knew they were looking at 'recapitalisation' (that can be via placing, rights issue, disposals/divestments) but they've already demonstrated they can expand cash runway in meantime whilst they consider best options TRX is only at 1.5p because of Woodford overhang NAV/share is 3p+ Typically in growth industries and market-leading Companies tend to trade at premia to NAV because that is what a new entrant would have to pay to replicate that position So we should be looking at a share price of 6p+ The fact the Chairman John Samuel bought at 10p is a further signal that value is SIGNIFICANTLY in excess of 1.5p here
22/1/2020
09:52
traderguy1: Anyone with an ounce of common sense would know if a placing was going to happen it would have happened today along with the trading update and higher share price. It’s obvious they are looking at other options. NOT A PLACING. This company will do well, by year end the share price will be much much higher than now. TRX is going to do well... Ignore the idiots
21/1/2020
14:08
the stigologist: This needs saying and re-iterating for the thick kids at the back of the class TRX is only at 1.7p because of Woodford overhang NAV/share is 3p+ Typically in growth industries and market-leading Companies tend to trade at premia to NAV because that is what a new entrant would have to pay to replicate that position So we should be looking at a share price of 6p+ The fact the Chairman bought at 10p is a further signal that value is SIGNIFICANTLY in excess of 1.7p here hTtps://twitter.com/Stockonomist/status/1219621369140391941?s=20 Thanks for coming to my TED Talk
15/1/2020
22:24
the stigologist: Good post from a.n.other forum Anyhow now onto TRX. This company has spent £10’s millions developing their FDA approved portfolio. The market Tissue Regenix operate it is significantly in growth. The ambient stable technology offered by TRX is a huge benefit as it removes the expensive chilled distribution costs relied upon by their competitors. Tissue Regenix is a young company with a CFO now acting as CEO so don’t expect fireworks from their PR team. He is calculated and knows what needs to be done to recover the MCAP to £100m. Now look over the Atlantic. The majority of sales are in the USA along with production. This would make a perfect marriage with one of the major distributors like Medline or McKesson, who are alway looking for new tech companies to buy. I personally hope this doesn’t happen, as within a year I believe the share price will be plus 10p. Finance update should be black and white. MIDCAP will be the ongoing partner short and medium term. They just want TRX to spend their own money before they spend theirs. (RNS could have been worded better). With all focus on America we forget the ROW sales opportunities. Following the positive move to outsource some of the less critical portfolio, this will increase availability and allow the business to open up new markets. Don’t forget we can buy tomorrow thanks to Woodford. That is the only reason. I am making the most of this and will continue to buy and hold. For me this is one of the most exciting companies on AIM. I feel for those who lost money on DEB and more recently LEK. In the world of AIM their are plenty of wasps, but once in a while you find the Queen Bee. Good luck all genuine holders.
14/1/2020
09:55
traderguy1: 8p easy TRX With a current market cap of 16m, Cellright alone was purchased by TRX for US30 million. Then you got the main outlining business itself. This should be way over 100 million market cap right now. That’s an 8p share price. It’s been way higher. 16m now is just ridiculously low. We are just getting going now, the beginning of a major re-rate.
08/1/2020
14:56
traderguy1: TRX With a current market cap of 12m. Cellright alone was purchased by TRX for US30 million. Then you got the main outlining business itself. This should be way over 100 million market cap right now. That’s an 8p share price. It’s been way higher. 12m now is just ridiculously low.
01/1/2020
16:39
holycow1: So you are saying that Midcap have said to TRX go and get a placing before we part with our money? Their are many ways to restructure a company. hxxps://corporatefinanceinstitute.com/resources/knowledge/finance/recapitalization/ Attention to... Leveraged Recapitalization In a leveraged recapitalization, the company replaces part of its equity with additional debt and thereby changes its capital structure. One form of leveraged recapitalization might be a company issuing bonds to raise money. A company may resort to leveraged recapitalization if its share price declines. In this case, the company may issue debt securities to fund buying back its outstanding shares in the market. By reducing the number of outstanding shares, the company expects to increase the per share price.
14/11/2019
07:06
irondick: LSE:TRX Tissue Regenix Share News (TRX) 2 Follow TRX Share Name Share Symbol Market Type Share ISIN Share Description Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade 0.00 0.0% 1.125 1.10 1.15 0.00 0.00 0.00 0.00 00:00:00 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 11.6 -8.9 -0.7 - 13 Print Alert Tissue Regenix Group PLC Updated loan facility agreement with MidCap 14/11/2019 7:01am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Thursday 14 November 2019 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 3497T Tissue Regenix Group PLC 14 November 2019 This announcement contains inside information Tissue Regenix Group plc Updated loan facility agreement with MidCap Leeds, 14 November 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company, announces the terms of a revised agreement ("Agreement") that it has entered into with MidCap Financial Trust ("MidCap") with regard to the term loan credit facility (the "Term Loan") and revolving credit facility (the "RCF") (together, the "Facilities"). This follows the Company's announcement on 11 November 2019. Further details of the Facilities are contained in the Company's announcement on 4 June 2019. Following engagement with MidCap the Company has successfully renegotiated the Term Loan, agreeing an immediate repayment of $5.5 million of the outstanding Term Loan ("Repayment"). Under the terms of the Agreement, MidCap has agreed to waive the prepayment fee and defer a portion of the exit fee due thereunder until the earlier of the date upon which the Term Loan is repaid or the maturity date. The remaining balance of $2.0 million of the Term Loan currently drawn down by the Company will remain in place ("Tranche One"). The Company will also continue to have access to draw down the remainder of the RCF, which is calculated based on the underlying inventory and receivables on the balance sheet and eligibility thereof. In addition, MidCap has agreed to suspend its testing of the financial banking covenants until 30 June 2020, when it will recommence with reduced revenue targets. MidCap has agreed to add the repaid $5.5 million of Tranche One to its commitment amount under tranche two of the Term Loan, which consisted of $5.0 million and now consists of $10.5 million ("Tranche Two"). Access to Tranche Two and the final tranche of $2.5 million ("Tranche Three") of the Term Loan remain in place, however the drawdown of these tranches is now subject to MidCap's discretion and satisfactory recapitalisation of the Company at that time. The repayment of the outstanding principal of the Term Loan will begin on 1 July 2020 and will amortise on a straight-line basis across 48 months.
Tissue Regenix share price data is direct from the London Stock Exchange
Your Recent History
LSE
TRX
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200126 04:51:33